Reportedly, factors such as a heavier tumor mutation load, increased frequency of TILs and enhanced expression of PD-L1 may contribute to increased immunogenicity for TNBC, thus, TNBC patients are expected to benefit from ICIs (20). This evidence concerns the gene CD274 and neoplasm.